10-Q: IN8bio Reports First Quarter 2024 Financial Results, Cites Going Concern Uncertainty

IN8bio's first quarter 2024 results show a net loss of $8.6 million and highlight substantial doubt about the company's ability to continue as a going concern.

Summary

• IN8bio, a clinical-stage biopharmaceutical company, reported a net loss of $8.6 million for the three months ended March 31, 2024, compared to a net loss of $7.5 million for the same period in 2023.
• The company's research and development expenses increased to $4.9 million, up from $4.4 million in the prior year, primarily due to increased personnel costs.
• General and administrative expenses also rose to $3.7 million, compared to $3.5 million in the prior year, due to increased personnel costs and rent expense.
• As of March 31, 2024, IN8bio had cash of $13.0 million, which is projected to fund operations only into January 2025, raising substantial doubt about the company's ability to continue as a going concern.
• The company is exploring options to raise additional capital through equity and/or debt offerings, strategic collaborations, and licensing agreements.
• IN8bio may receive an additional $14.8 million if Series A warrants are exercised and up to $17.7 million from Series B warrants, but there is no assurance these warrants will be exercised.
• The company has an accumulated deficit of $99.8 million as of March 31, 2024.
• The company has not generated any revenue from product sales since its inception.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a net loss, increasing expenses, and a going concern warning. While there are some positive developments in the pipeline, the overall sentiment is negative due to the company's precarious financial situation.

Positives

• The company has completed primary enrollment of the Phase 1 clinical trial for INB-100 and is expanding the trial with an additional ten patients.
• The company presented preclinical data for INB-300 at the AACR Annual Meeting in 2024.
• The company has produced hundreds of millions of iPSC derived gamma-delta T cells from single iPSC clones.
• The company has an oral presentation at the American Society of Gene & Cellular Therapy Annual Meeting in May 2024 on the characterization of DeltEx DRI products.

Negatives

• The company has incurred significant operating losses since inception and anticipates continuing to incur substantial losses.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has not generated any revenue from product sales since its inception.
• The company's existing cash is projected to fund operations only into January 2025.
• The company is dependent on raising additional capital to fund its operations.
• The company's ability to raise capital may be limited by applicable laws and regulations.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company may be forced to delay, reduce, or terminate development programs if additional funding is not secured.
• Raising additional capital may cause dilution to existing stockholders.
• The company's outstanding warrants may not be exercised, and the company may not receive any cash proceeds from them.
• The company has a limited operating history and no products approved for commercial sale.
• The company is dependent on the successful clinical development, regulatory approval, and commercialization of its product candidates.
• The company faces significant competition from companies with greater resources.
• The company's manufacturing process is complex, and the company may encounter difficulties in production.
• The company relies on third-party contractors for manufacturing, and their failure to perform could harm the business.
• The company is dependent on a single third-party supplier for its automated manufacturing device and lentiviral vectors.
• The company relies on third-party healthcare professionals to administer its cell therapies, and errors could harm the business.
• The company's intellectual property is critical to its business, and breaches of license agreements could result in loss of rights.
• The company may not be able to obtain and maintain patent protection for its product candidates and technology.
• The company is dependent on key personnel, and the loss of their services could harm the business.
• The company may face legal proceedings and other claims, which may require expensive and time-consuming litigation.
• Unstable market and economic conditions may have serious adverse consequences on the company's business and share price.
• The company maintains cash deposits in excess of federally insured limits, which could be at risk if financial institutions fail.

Future Outlook

The company expects to incur additional losses in the future as it advances its product candidates through clinical trials, seeks to expand its product candidate portfolio, grows its capabilities, and incurs costs associated with operating as a public company. The company plans to file several company-sponsored IND applications for its pipeline product candidates over the next few years.

Management Comments

• Management has developed plans to raise additional capital through equity and/or debt offerings, including through the ATM program.
• Management is also exploring strategic collaborations, licensing, or other arrangements to support the development of product candidates.

Industry Context

The company is operating in the competitive field of immuno-oncology, which is characterized by rapid advancements and significant investment. The company's focus on gamma-delta T cell therapies is a novel approach, but it faces competition from companies with more established technologies and greater resources.

Comparison to Industry Standards

• The company's cash burn rate is high compared to other clinical-stage biopharmaceutical companies, raising concerns about its ability to continue operations without additional funding.
• The company's reliance on third-party manufacturers is common in the industry, but it also introduces risks related to supply chain and quality control.
• The company's focus on gamma-delta T cell therapies is a novel approach, but it is also unproven and carries significant risks.
• The company's clinical trial progress is in line with other companies in the early stages of development, but the company needs to demonstrate efficacy in larger trials to secure regulatory approval.
• The company's financial position is weaker than many of its peers, as it has not generated any revenue and has a significant accumulated deficit.

Management Changes

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional capital.
• Employees may be impacted by potential cost-cutting measures or delays in development programs.
• Customers and patients may experience delays in the development and availability of new therapies.
• Suppliers and creditors may face increased risk due to the company's financial instability.

Next Steps

• The company plans to continue clinical development of INB-400, INB-200, and INB-100.
• The company plans to advance its preclinical pipeline and internal research and development capabilities.
• The company plans to seek potential collaborative partners for its earlier stage assets.
• The company plans to file several company-sponsored IND applications for its pipeline product candidates over the next few years.

Key Dates

Keywords

gamma-delta T cells, immunotherapy, glioblastoma, hematologic malignancies, clinical trials, biopharmaceutical, cell therapy, warrants, going concern, DeltEx platform